Alumis Inc Asset Resilience Ratio
Alumis Inc asset resilience ratio. Alumis Inc (ALMS) has an Asset Resilience Ratio of 78.23% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ALMS cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Alumis Inc (2022–2025)
Asset resilience ratio of Alumis Inc from 2022 to 2025. This chart shows how Alumis Inc's Asset Resilience Ratio has changed over time. Read Alumis Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Alumis Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Alumis Inc total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $438.59 Million | 78.23% |
| Total Liquid Assets | $438.59 Million | 78.23% |
Asset Resilience Insights
- Very High Liquidity: Alumis Inc maintains exceptional liquid asset reserves at 78.23% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Alumis Inc Industry Peers by Asset Resilience Ratio
Compare Alumis Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Alumis Inc Asset Resilience Ratio by Year (2022–2025)
Alumis Inc asset resilience ratio by year from 2022 to 2025. The table below shows the annual Asset Resilience Ratio data for Alumis Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 53.12% | $218.83 Million | $411.94 Million | +18.30pp |
| 2024-12-31 | 34.82% | $118.74 Million | $340.99 Million | +31.52pp |
| 2023-12-31 | 3.30% | $2.96 Million | $89.61 Million | -58.88pp |
| 2022-12-31 | 62.18% | $67.25 Million | $108.17 Million | -- |
About Alumis Inc
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment o… Read more